Johnson & Johnson Partners Boston University To Eradicate Lung Cancer

There is massive collaboration between Johnson and Johnson, a renowned company in the health industry who have partnered with Boston University to find a lasting cure for lung cancer.

This was unveiled at the annual BIO International Convention at the Boston Convention and Exhibition Center during a press conference attended by BU President Robert A. Brown and officials from the university and Johnson & Johnson. The company, which is based in New Brunswick, brief pressmen about the need to partner with the private sector to leverage their resources and their capabilities to innovate a lasting cure for lung cancer

Johnson & Johnson based in new jersey will co-sponsor the program for five years. This program is developing a cadre of scientists who have strong foundations in clinical research and research-related regulatory practices, with the goal of helping bridge the of cancer death in men and women in the United States, that kills about 154,000 people each year on lung cancer therapy

BU President Robert A. Brown said there a mutual agreement between the school and Johnson and Johnson to solidify ongoing collaborations and provide a vehicle for short- and longer-term exchanges of clinicians and scientists engaged in lung cancer research and how to detect early-screening tests for lung cancer, as well as medicines to arrest or eradicate the disease in its earliest stages.

Dr. Avrum Spira, a professor of medicine, pathology, and bioinformatics at BU, brief pressmen that successful mechanisms for promoting collaborating with Johnson & Johnson Innovations as global head of its lung cancer initiative are in place and will be a key member at he the new center.